Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors

Bibliography

• Cravatt BF, Prospero-Garcia O, Siuzdak G, Chemical characterization of a family of brain lipids that induce sleep. Science 1995;268:1506-9
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Giang DK, Mayfield SP, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-7
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Shov Y, Hashish I. Structure of cannabidiol. Tetrahedron 1963;19:2073-8
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7
   Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, International Union of Pharmocology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202
   PubMed Web of Science ®Google Scholar
• Piomelli D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003;4:873-84
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-55
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Demarest K, Patricelli MP, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-6
   PubMed Web of Science ®Google Scholar
• McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005;74:411-32
   PubMed Web of Science ®Google Scholar
• Ahn K, Mckinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008;108:1687-707
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Lashuel HA, Giang DK, Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 1998;37:15177-87
   PubMed Web of Science ®Google Scholar
• Wei BQ, Mikkelsen TS, McKinney MK, A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006;281:36569-78
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Cravatt BF. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry 1999;38:14125-30
   PubMed Web of Science ®Google Scholar
• Lodola A, Mor M, Hermann JC, QM/MM modeling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun 2005;35:4399-401
   PubMed Web of Science ®Google Scholar
• Bracey MH, Hanson MA, Masuda KR, Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002;298:1793-6
   PubMed Web of Science ®Google Scholar
• Mileni M, Johnson DS, Wang Z, Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 2008;105:12820-4
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Mileni M, Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009;16:411-20
   PubMed Web of Science ®Google Scholar
• Mileni M, Garfunkle J, DeMartino JK, Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 2009;131:10497-506
   PubMed Web of Science ®Google Scholar
• Mileni M, Garfunkle J, Ezzili C, X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 2010;53:230-40
   PubMed Web of Science ®Google Scholar
• Fu J, Gaetani S, Oveisi F, Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR alpha. Nature 2003;425:90-3
   PubMed Web of Science ®Google Scholar
• Thabuis C, Tissot-Favre D, Bezelgues JB, Biological functions and metabolism of oleoylethanolamide. Lipids 2008;43:887-94
   PubMed Web of Science ®Google Scholar
• LoVerme J, La Rana G, Russo R, The search for the palmitoylethanolamide receptor. Life Sci 2005;77:1685-98
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-101
   PubMed Web of Science ®Google Scholar
• Costa B, Comelli F, Bettoni I, The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPAR gama receptors and neurotrophic factors. Pain 2008;139:541-50
   PubMed Web of Science ®Google Scholar
• Saghatelian A, McKinney MK, Bandell M, A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 2006;45:9007-15
   PubMed Web of Science ®Google Scholar
• Bradshaw HB, Rimmerman N, Hu S-J, Novel endogenous N-acyl glycines: identification and characterization. Vitamins and hormones 2009;81:191-205
   PubMed Web of Science ®Google Scholar
• Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998;422:69-73
   PubMed Web of Science ®Google Scholar
• Dinh TP, Carpenter D, Leslie FM, Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002;99:10819-24
   PubMed Web of Science ®Google Scholar
• Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48:5059-87
   PubMed Web of Science ®Google Scholar
• Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008;8:247-67
   PubMed Web of Science ®Google Scholar
• Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008;51:7327-43
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009;4:763-84
   PubMed Web of Science ®Google Scholar
• Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Invest Drugs 2010;11:51-62
   PubMed Web of Science ®Google Scholar
• Minkkila A, Saario SM, Nevalainen T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr Top Med Chem 2010;10:828-58
   PubMed Web of Science ®Google Scholar
• Bisogno T, Melck D, De Petrocellis L, Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochim Biophys Res Commun 1998;248:515-22
   PubMed Web of Science ®Google Scholar
• Maione S, De Petrocellis L, De Novellis V, Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007;150:766-81
   PubMed Web of Science ®Google Scholar
• Costa B, Bettoni I, Petrosino S, The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharm Res 2010;61:537-46
   Web of Science ®Google Scholar
• Koutek B, Prestwich GD, Howlett AC, Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994;269:22937-40
   PubMed Web of Science ®Google Scholar
• Patterson JE, Ollmann IR, Cravatt BF, Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J Am Chem Soc 1996;118:5938-45
   Web of Science ®Google Scholar
• Boger DL, Sato H, Lerner AE, Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg Med Chem Lett 1999;9:265-70
   PubMed Web of Science ®Google Scholar
• Boger DL, Sato H, Lerner AE, Exceptionally potent inhibitors of fatty acid amide hydrolase:the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97:5044-9
   PubMed Web of Science ®Google Scholar
• Boger DL, Miyauchi H, Hedrick MP. alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett 2001;11:1517-20
   PubMed Web of Science ®Google Scholar
• Boger DL, Miyauchi H, Du W, Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 2005;48:1849-56
   PubMed Web of Science ®Google Scholar
• Kimball FS, Romero FA, Ezzili C, Optimization of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:937-47
   PubMed Web of Science ®Google Scholar
• DeMartino JK, Garfunkle J, Hochstatter DG, Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2008;18:5842-6
   PubMed Web of Science ®Google Scholar
• Garfunkle J, Ezzili C, Rayl TJ, Optimization of the central hetercycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:4392-403
   PubMed Web of Science ®Google Scholar
• Edwards PD, Meyer EF, Vijayalakshmi J, Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl alpha-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J Am Chem Soc 1992;114:1854-63
   Web of Science ®Google Scholar
• Hardouin C, Kelso MJ, Romero FA, Structure-activity relationships of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2007;50:3359-68
   PubMed Web of Science ®Google Scholar
• Apodaca R, Breitenbucher JG, Epperson MT, Preparation of piperidinylbutanoyl oxazoles as fatty acid amide hydrolase (FAAH) modulators. WO2007061862; 2007
   Google Scholar
• Apodaca R, Breitenbucher JG, Chambers A. Preparation of oxazolyl piperidinyl methanones as modulators of fatty acid amide hydrolase. WO2007140005; 2007
   Google Scholar
• Timmons A, Seierstad M, Apodaca R, Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2008;18:2109-13
   PubMed Web of Science ®Google Scholar
• Tarzia G, Duranti A, Tontini A, Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 2003;46:2352-60
   PubMed Web of Science ®Google Scholar
• Mor M, Rivara S, Lodola A, Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004;47:4998-5008
   PubMed Web of Science ®Google Scholar
• Basso E, Duranti A, Mor M, Tandem mass spectrometric data – FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom 2004;39:1450-5
   PubMed Web of Science ®Google Scholar
• Tarzia G, Duranti A, Gatti G, Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem 2006;1:130-9
   PubMed Web of Science ®Google Scholar
• Mor M, Lodola A, Rivara S, Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of the biphenyl-3-yl alkylcarbamates. J Med Chem 2008;51:3487-98
   PubMed Web of Science ®Google Scholar
• Vacondio F, Silva C, Lodola A, Structure-property relationships of a class of carbamate based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem 2009;4:1495-504
   PubMed Web of Science ®Google Scholar
• Clapper JR, Vacondio F, King AR, A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem 2009;4:1505-13
   PubMed Web of Science ®Google Scholar
• Mileni M, Kamtekar S, Wood DC, Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol 2010;400:743-54
   PubMed Web of Science ®Google Scholar
• Saario SM, Poso A, Juvonen RO, Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem 2006;49:4650-6
   PubMed Web of Science ®Google Scholar
• Minkkila A, Myllymaki MJ, Saario SM, The synthesis and biological evaluation of para-substitued phenolic N-alkylcarbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem 2009;44:2994-3008
   PubMed Web of Science ®Google Scholar
• Myllymaki MJ, Kasnanen H, Kataja AO, Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: insight into FAAH enantioselectivity by molecular docking and interaction fields. Eur J Med Chem 2009;44:4179-91
   PubMed Web of Science ®Google Scholar
• Kasnanen H, Myllymaki MJ, Minkkila A, 3-Heterocycl-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies. ChemMedChem 2010;5:213-31
   PubMed Web of Science ®Google Scholar
• Gattinoni S, Simone CD, Dallavalle S, Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. ChemMedChem 2010;5:357-60
   PubMed Web of Science ®Google Scholar
• Sit SY, Xie K. Preparation of bisarylimidazolyl fatty acid amide hydrolase inhibitors for treatment of pain. WO2002087569; 2002
   Google Scholar
• Sit SY, Xie K, Deng H. Preparation of (hetero)aryl carbamates and oximes as fatty acid amide hydrolase inhibitors. WO2003065989; 2003
   Google Scholar
• Sit SY, Conway C, Bertekap R, Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2007;17:3287-91
   PubMed Web of Science ®Google Scholar
• Sit SY, Conway CM, Xie K, Oxime carbamates-discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett 2010;20:1275-7
   Web of Science ®Google Scholar
• Minetti P, Cabri W, Borsini F, Preparation of oxime carbamoyl derivatives as modulators of fatty acid amides hydrolase. WO2009138416; 2009
   Google Scholar
• Abouabdellah A, Gorlitzer J, Hamley P, Alkylthiazolyl carbamates, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010010288; 2010
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00822744
   Google Scholar
• Long JZ, Nomura DK, Vann RE, Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009;106:20270-5
   PubMed Web of Science ®Google Scholar
• Morera E, De Petrocellis L, Morera L, Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett 2009;19:6806-9
   PubMed Web of Science ®Google Scholar
• Ishii T, Sugane T, Maeda J, Preparation of pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivatives as FAAH inhibitors. WO2006088075; 2006
   Google Scholar
• Aoki S, Munakata R, Kawano N, Preparation of azole compounds for treating neuropathic pain. WO2010007966; 2010
   Google Scholar
• Ishii T, Sugane T, Munakata R, Carbamate compound or salt thereof. WO2010053120; 2010
   Google Scholar
• Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 2006;128:9699-704
   PubMed Web of Science ®Google Scholar
• Keith JM, Apodaca R, Xiao W, Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2008;18:4838-43
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Fitzgerald LR, Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007;46:13019-30
   PubMed Web of Science ®Google Scholar
• Johnson DS, Ahn K, Kesten S, Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2009;19:2865-9
   PubMed Web of Science ®Google Scholar
• Wang JL, Bowen SJ, Schweitzer BA, Structure based design of novel irreversible FAAH inhibitors. Bioorg Med Chem Lett 2009;19:5970-4
   PubMed Web of Science ®Google Scholar
• Fay LK, Johnson DS, Lazerwith SE, Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors. WO2008047229; 2008
   Google Scholar
• Meyers MJ, Pelc MJ, Thorarensen A. 4-[3-(Aryloxy)benzylidene]-3-methylpiperidine aryl carboxamide compounds useful as FAAH inhibitors and their preparation. WO2009127949; 2009
   Google Scholar
• Fay LK, Johnson DS, Meyers MJ, Ether benzylidene piperidine aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127944; 2009
   Google Scholar
• Meyers MJ, Pelc MJ, Thorarensen A, 4-[3-(Aryloxy)benzylidene]-3-methylpiperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127948; 2009
   Google Scholar
• Meyers MJ, Pelc MJ, Schweitzer BA, 4-Benzylidene-3-methylpiperidine aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127946; 2009
   Google Scholar
• Fay LK, Johnson DS, Meyers MJ, Ether benzylidene piperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127943; 2009
   Google Scholar
• Long SA, Meyers MJ, Pelc MJ, 7-Azaspiro[3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase. WO2010049841; 2010
   Google Scholar
• Long SA, Meyers MJ, Pelc MJ, 1-Oxa-8-azaspiro[4,5]decane-8-carboxamide compounds as FAAH inhibitors. WO2010058318; 2010
   Google Scholar
• Available from: http://media.pfizer.com/files/investors/presentations/acr_102808_v2.pdf
   Google Scholar
• Roughley S, Walls S, Hart T, Azetidine derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof. WO2009109743; 2009
   Google Scholar
• Hart T, Macias AT, Benwell K, Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett 2009;19:4241-4
   PubMed Web of Science ®Google Scholar
• Even L, Hoornaert C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo-[4,5-b]pyridin-1-yl)methanones and (piperidin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145839; 2008
   Google Scholar
• Even L, Hoornaert C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo-[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145843; 2008
   Google Scholar
• Makriyannis A, Pandarinathan L, Zvonok N, Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors. WO2009117444; 2009
   Google Scholar
• Ishii T, Sugane T, Kakefuda A, Preparation of piperazine-1-carboxamide and piperidine-1-carboxamide derivatives as inhibitors of fatty acid amide hydrolase (FAAH). WO2008023720; 2008
   Google Scholar
• Minkkila A, Saario S, Kasnanen H, Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:7057-60
   PubMed Web of Science ®Google Scholar
• Behnke ML, Castro AC, Evans, CA, Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors. WO2009126691; 2009
   Google Scholar
• Adams J, Behnke ML, Castro AC, Preparation of arylboronates as inhibitors of fatty acid amide hydrolase. WO2008063300; 2008
   Google Scholar
• Behnke ML, Castro AC, Evans CA, Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors. WO2009126691; 2009
   Google Scholar
• Urbach A, Muccioli GG, Stern E, 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett 2008;18:4163-7
   PubMed Web of Science ®Google Scholar
• Feledziak M, Michaux C, Urbach A, beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase. J Med Chem 2009;52:7054-68
   PubMed Web of Science ®Google Scholar
• Wilmouth RC, Kassamally S, Westwood NJ, Mechanistic insight into the inhibition of serine proteases by monocyclic lactams. Biochemistry 1999;38:7989-98
   PubMed Web of Science ®Google Scholar
• Lin LS, Chang LL, Chobanian H, Pyrazole derivatives useful as inhibitors of FAAH and their preparation and use in the treatment of diseases. WO2009151991; 2009
   Google Scholar
• Lin LS, Chioda MD, Liu P, Preparation of imidazole derivatives useful as inhibitors of FAAH. WO2009152025; 2009
   Google Scholar
• Chobanian H, Lin LS, Liu P, Preparation of oxazole derivatives as inhibitors of FAAH. WO2010017079; 2010
   Google Scholar
• Kelly MG, Kincaid J, Gowlugari S, Preparation of substituted naphthyridines as FAAH modulators. WO2009011904; 2009
   Google Scholar
• Kaub C, Gowlugari S, Kincaid J, Compounds useful as faah modulators and uses thereof. WO2010039186; 2010
   Google Scholar
• Apodaca R, Breitenbucher JG, Chambers A, Preparation of aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase. WO 2009105220; 2009
   Google Scholar
• Ma Z, Gustin DJ, Li Y, Identification of a potent, non-covalent series of fatty acid amide hydrolase (FAAH) inhibitors. Abstracts of Papers, 237th ACS National Meeting; Salt Lake City, UT, United States, 22 – 26 March, 2009; MEDI-105
   Google Scholar
• Talley JJ, Sprott K, Pearson JP, Indole compounds for treating pain, inflammation and other conditions. WO2008019357; 2008
   Google Scholar
• Bartolini W, Cali BN, Chen B, Useful indole compounds. WO2007070892; 2007
   Google Scholar
• Available from: http://www.leaddiscovery.co.uk/trials/8266
   Google Scholar
• Wang X, Sarris K, Kage K, Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem 2009;52:170-80
   PubMed Web of Science ®Google Scholar
• Minkkila A, Savinainen JR, Kasnanen H, Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. ChemMedChem 2009;4:1253-9
   PubMed Web of Science ®Google Scholar
• Learmonth DA, Kiss LE, Beliaev A, 5-O-Substituted 3-N-phenyl-1,3,4-oxadiazolones as FAAH inhibitors and their preparation and use in the treatment of diseases. WO2009084970; 2009
   Google Scholar
• Forster L, Ludwig J, Kaptur M, 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2 alpha and fatty acid amide hydrolase. Bioorg Med Chem 2010;18:945-52
   PubMed Web of Science ®Google Scholar
• Justinova Z, Mangieri RA, Bortolato M, Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008:64:930-7
   PubMed Web of Science ®Google Scholar
• Maccarrone M. Endocannabinoids: friends and foes of reproduction. Progress in Lipid Research 2009;48:344-54
   PubMed Web of Science ®Google Scholar
• Lewis SE, Maccarrone M. Endocannabinoids, sperm biology and human fertility. Pharm Res 2009;60:126-31
   Web of Science ®Google Scholar
• Francavilla F, Battista N, Barbonetti A, Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology 2009;150:4692-700
   Google Scholar
• Habayeb OM, Taylor AH, Finney M. Plasma anandamide concentration and pregnancy outcome in woman with threatened miscarriage. J Am Med Assoc 2008;299:1135-6
   PubMed Web of Science ®Google Scholar
• Sun X, Wang H, Okabe M, Genetic loss of FAAH compromises male fertility in mice. Biol Reprod 2009;80:235-42
   PubMed Web of Science ®Google Scholar
• Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008;19:344-8
   PubMed Web of Science ®Google Scholar
• Capasso R, Izzo AA. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. J Neuroendocrin 2008;20(S1):39-46
   PubMed Web of Science ®Google Scholar
• Smith PJW, McQueen DS. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 2001;134:655-63
   PubMed Web of Science ®Google Scholar
• Hogestatt ED, Zygmunt PM. Cardiovascular pharmacology of anandamide. Prostaglandins, Leukot Essent Fatty Acids 2002;66:343-51
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Osei-Hyiaman D, Hemodynamic profile, responsiveness to anandamide and barareflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2005;289:H533-41
   PubMed Web of Science ®Google Scholar
• Batkai S, Pacher P, Ose-Hyiaman D, Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110:1996-2002
   PubMed Web of Science ®Google Scholar
• Awumey EM, Howlett AC, Diz DI. Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism. Am J Physiol Heart Circ Physiol 2005;289:H520-1
   PubMed Web of Science ®Google Scholar